OCUL · Ocular Therapeutix, Inc.

Summary

Ocular Therapeutix, Inc. will make available slides under the Investors section of its corporate website at 4:15 pm Eastern Time on February 27, 2026, detailing results from the SOL-1 Phase 3 superiority clinical trial of AXPAXLI (OTX-TKI) for wet age-related macular degeneration, to be presented at the 49th Macula Society Annual Meeting.

Key takeaways

• Slides available at 4:15 pm ET on February 27, 2026, on Investors section of corporate website
• Presentation at 49th Macula Society Annual Meeting on February 27, 2026
• Detailed results from SOL-1 Phase 3 superiority clinical trial
• AXPAXLI (also known as OTX-TKI)
• Treatment for wet age-related macular degeneration